Nothing Special   »   [go: up one dir, main page]

ATE469658T1 - Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung - Google Patents

Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung

Info

Publication number
ATE469658T1
ATE469658T1 AT05856275T AT05856275T ATE469658T1 AT E469658 T1 ATE469658 T1 AT E469658T1 AT 05856275 T AT05856275 T AT 05856275T AT 05856275 T AT05856275 T AT 05856275T AT E469658 T1 ATE469658 T1 AT E469658T1
Authority
AT
Austria
Prior art keywords
receptors
combination therapies
against multiple
toll
therapies against
Prior art date
Application number
AT05856275T
Other languages
English (en)
Inventor
Greg Elson
Olivier Leger
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Application granted granted Critical
Publication of ATE469658T1 publication Critical patent/ATE469658T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT05856275T 2004-12-10 2005-12-12 Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung ATE469658T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63542104P 2004-12-10 2004-12-10
PCT/IB2005/004174 WO2006077471A2 (en) 2004-12-10 2005-12-12 Combining therapies targeting multiple toll-like receptors and use thereof

Publications (1)

Publication Number Publication Date
ATE469658T1 true ATE469658T1 (de) 2010-06-15

Family

ID=36692602

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05856275T ATE469658T1 (de) 2004-12-10 2005-12-12 Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung

Country Status (12)

Country Link
US (1) US8029794B2 (de)
EP (1) EP1830881B1 (de)
JP (2) JP5118491B2 (de)
AT (1) ATE469658T1 (de)
AU (1) AU2005325482B2 (de)
CA (1) CA2593561C (de)
DE (1) DE602005021694D1 (de)
DK (1) DK1830881T3 (de)
ES (1) ES2348792T3 (de)
PL (1) PL1830881T3 (de)
PT (1) PT1830881E (de)
WO (1) WO2006077471A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028509A1 (en) 2003-09-23 2005-03-31 Technische Universitaet Muenchen Tlr2 antagonistic antibody and use thereof
BRPI0609302A2 (pt) 2005-04-15 2011-10-11 Becton Dickinson Co métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse
WO2008132516A1 (en) * 2007-04-26 2008-11-06 Opsona Therapeutics Limited Toll-like receptor binding epitope and compositions for binding thereto
SI2173381T1 (sl) * 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
CA2691784C (en) * 2007-06-28 2016-11-01 Opsona Therapeutics Limited Composition and method for treatment of autoimmune disease
US20100278817A1 (en) 2007-07-05 2010-11-04 Opsona Therapeutics Ltd. Compounds and methods for the treatment of renal disease
EP2170366B1 (de) * 2007-08-03 2013-11-06 Opsona Therapeutics Limited Verwendung eines tlr-2 antagonisten zur behandlung von reperfusionsverletzungen und gewebeschäden
EP2214692A2 (de) * 2007-10-31 2010-08-11 Centocor Ortho Biotech Inc. Verwendung von toll-like-rezeptor-4-antagonisten zur behandlung oder prävention von osteoarthritischen erkrankungen
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
CA2727790A1 (en) * 2008-06-13 2009-12-17 Synvista Therapeutics, Inc. Reagents and methods for detecting a polymorphic protein
JP2012504953A (ja) 2008-10-07 2012-03-01 ノビミューン エスアー Ｉｌ−１７媒介性トランスフェクション法
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137844A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US8613924B2 (en) * 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
PL2831117T3 (pl) 2012-03-29 2018-03-30 Novimmune Sa Przeciwciała anty-TLR4 i ich zastosowania
EP2722342A1 (de) * 2012-10-19 2014-04-23 Opsona Therapeutics Limited Verfahren und Zusammensetzungen zur Behandlung von Pankreaskrebs
US10047164B2 (en) 2012-10-19 2018-08-14 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
JP6450594B2 (ja) * 2012-12-28 2019-01-09 持田製薬株式会社 プレセプシン測定による炎症性腸疾患の診断
US9688769B2 (en) * 2013-10-22 2017-06-27 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
ES2709996T3 (es) * 2014-02-28 2019-04-22 Astellas Pharma Inc Nuevo anticuerpo biespecífico que se une al TLR2 humano y al TLR4 humano
US9730983B2 (en) * 2015-10-02 2017-08-15 Chih-Yuan MA Methods for treatment of CD14-mediated disorders and responses
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
US20190315878A1 (en) * 2016-11-07 2019-10-17 Argos Therapeutics Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
WO2018112223A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
JP7016184B2 (ja) * 2018-03-12 2022-02-21 学校法人日本医科大学 ｍｉｃｒｏＲＮＡ－２１を標的とした変形性関節症による疼痛の緩和
WO2021243396A1 (en) * 2020-06-01 2021-12-09 Implicit Bioscience Limited Therapeutic methods of using cd 14 antagonistic antibodies in treating conditions associated with a coronavirus infection including sars-cov-2 (covid-19)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028025A1 (en) * 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
US20030032090A1 (en) * 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
AU2001290315A1 (en) * 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
EP1420798A4 (de) 2001-08-10 2007-07-25 Eisai Co Ltd Behandlung und prävention von erkrankungen und zuständen im zusammenhang mit hitzeschock-protein
IL160561A0 (en) * 2001-09-07 2004-07-25 Univ Boston Method and composition for treating immune complex associated disorders
WO2005028509A1 (en) 2003-09-23 2005-03-31 Technische Universitaet Muenchen Tlr2 antagonistic antibody and use thereof
WO2005047330A1 (ja) 2003-11-17 2005-05-26 Japan Science And Technology Agency Ｔｌｒ４−ｍｄ−２複合体を標的としたエンドトキシンショック治療剤
EP1711531B9 (de) * 2003-12-10 2012-07-25 Novimmune SA Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof

Also Published As

Publication number Publication date
DE602005021694D1 (de) 2010-07-15
WO2006077471A2 (en) 2006-07-27
CA2593561C (en) 2017-01-03
EP1830881A2 (de) 2007-09-12
EP1830881B1 (de) 2010-06-02
US8029794B2 (en) 2011-10-04
JP5118491B2 (ja) 2013-01-16
JP2012197316A (ja) 2012-10-18
JP2008523048A (ja) 2008-07-03
DK1830881T3 (da) 2010-09-20
WO2006077471A3 (en) 2007-04-19
PT1830881E (pt) 2010-08-30
ES2348792T3 (es) 2010-12-14
US20060165686A1 (en) 2006-07-27
CA2593561A1 (en) 2006-07-27
PL1830881T3 (pl) 2010-11-30
AU2005325482B2 (en) 2011-06-16
AU2005325482A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
MX2009013199A (es) Anticuerpos anti-notch1 nnr y sus metodos de uso.
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
TW200603828A (en) Treatment of disorders
CY1112912T1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
TW200709817A (en) Platform antibody compositions
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
HK1154904A1 (zh) 天然 抗體及其抑制劑
WO2007038407A3 (en) Compositions and methods for treating nervous system disorders
UA100984C2 (ru) Антитела против nrr notch1 и способы их применения
BRPI0512874A (pt) composições e métodos para o tratamento de distúrbios inflamatórios
CY1114825T1 (el) Συνθεσεις και μεθοδοι αγωγης διαταραχων υπερπλασιας κυτταρων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1830881

Country of ref document: EP